Harvard Bioscience Total Current Liabilities

The latest total current liabilities for HBIO is $24M as of March 2026. That compares with $56M in the prior-year period — down 57.1% year over year. Investors often review this figure alongside Harvard Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, HBIO's total current liabilities moved from $56M to $24M — a 57.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Harvard Bioscience's operating scale or balance-sheet position.

A total current liabilities figure of $24M for HBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting HBIO's total current liabilities ($24M), review year-over-year change from $56M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Harvard Bioscience's total current liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.